Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

January 29, 2025

Study Completion Date

January 29, 2025

Conditions
Sickle Cell Disease
Interventions
PROCEDURE

Haploidentical Bone Marrow Transplantation

Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.

DRUG

Hydroxyurea

HU will be given daily at 30mg/kg from Day -70 through Day -10.

DRUG

Rabbit-ATG

Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.

DRUG

Thiotepa

Thiotepa will be given at 10mg/kg on Day -7

DRUG

Fludarabine

Fludarabine will be given at 30mg/m2 from Day -6 to Day -2

DRUG

Cyclophosphamide

Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.

RADIATION

Total Body Irradiation

Total Body Irradiation will be given at 200cGy on Day -1

DRUG

Mesna

Mesna will be given at 40mg/kg on Days +3 and +4

Trial Locations (32)

11042

Northwell Health/Monter Cancer Center, Lake Success

14203

Roswell Park Cancer Center, Buffalo

15260

University of Pittsburgh, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

21287

Johns Hopkins University, Baltimore

27705

Duke University Medical Center, Durham

28203

Levine Children's Hospital, Charlotte

30342

Northside Hospital, Atlanta

32610

University of Florida College of Medicine, Gainesville

33155

Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami

33612

H. Lee Moffitt Cancer Center, Tampa

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

38104

Methodist Healthcare/West Cancer Center, Memphis

38105

St. Jude Children's Research Hospital, Memphis

44106

University Hospitals of Cleveland/Case Western, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

46020

Riley Children's Hospital at IU Health, Indianapolis

46202

Indiana University Medical Center, Indianapolis

48201

Children's Hospital of Michigan, Detroit

49503

Helen Devos Children's at Spectrum Health, Grand Rapids

53226

The Medical College of Wisconsin, Wauwatosa

63104

Cardinal Glennon Children's Hospital, St Louis

63110

Washington University, St. Louis, St Louis

77030

Texas Children's Hospital (Baylor), Houston

University of Texas/MD Anderson Cancer Center, Houston

78229

Texas Transplant Institute, San Antonio

80045

University of Colorado - Denver/Children's Hospital of Colorado, Aurora

94609

UCSF Benioff Children's Hospital Oakland, Oakland

98109

Fred Hutchinson Cancer Research Center, Seattle

07601

Hackensack University Medical Center, Hackensack

43205-2696

Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Blood and Marrow Transplant Clinical Trials Network

NETWORK

collaborator

National Marrow Donor Program

OTHER

lead

Medical College of Wisconsin

OTHER

NCT03263559 - Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) | Biotech Hunter | Biotech Hunter